Puma Biotechnology Inc (NASDAQ:PBYI) Receives Consensus Recommendation of “Hold” from Brokerages

Puma Biotechnology Inc (NASDAQ:PBYI) has been assigned an average rating of “Hold” from the thirteen analysts that are currently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a sell rating and eight have issued a hold rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $24.25.

A number of research firms have recently issued reports on PBYI. Citigroup reissued a “buy” rating on shares of Healthequity in a research report on Friday, May 10th. Goldman Sachs Group upgraded shares of Koninklijke KPN from a “neutral” rating to a “buy” rating in a report on Wednesday, May 29th. Cowen restated a “hold” rating and issued a $28.00 target price on shares of Puma Biotechnology in a report on Friday, July 5th. JPMorgan Chase & Co. set a €52.00 ($60.47) target price on shares of Vonovia and gave the stock a “buy” rating in a report on Friday, May 10th. Finally, Zacks Investment Research lowered shares of W. R. Grace & Co from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st.

Shares of PBYI stock traded down $0.35 on Tuesday, reaching $10.20. 1,100,479 shares of the company were exchanged, compared to its average volume of 1,306,817. The firm has a 50-day simple moving average of $12.98. The company has a debt-to-equity ratio of 4.08, a current ratio of 2.53 and a quick ratio of 2.50. Puma Biotechnology has a one year low of $10.15 and a one year high of $54.20.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.69) by $0.43. The company had revenue of $99.10 million for the quarter, compared to analysts’ expectations of $67.25 million. Puma Biotechnology had a negative net margin of 35.01% and a negative return on equity of 245.22%. The business’s revenue was up 49.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.03 EPS. On average, analysts anticipate that Puma Biotechnology will post -2.49 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. NumerixS Investment Technologies Inc increased its stake in Puma Biotechnology by 969.5% in the 4th quarter. NumerixS Investment Technologies Inc now owns 2,139 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 1,939 shares during the last quarter. Amundi Pioneer Asset Management Inc. purchased a new stake in Puma Biotechnology in the 4th quarter valued at about $61,000. SG Americas Securities LLC purchased a new stake in Puma Biotechnology in the 1st quarter valued at about $210,000. Stephens Inc. AR purchased a new stake in Puma Biotechnology in the 1st quarter valued at about $240,000. Finally, Oppenheimer Asset Management Inc. increased its stake in Puma Biotechnology by 28.9% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 6,477 shares of the biopharmaceutical company’s stock valued at $251,000 after buying an additional 1,454 shares during the last quarter. Institutional investors own 86.74% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous).

See Also: What does a hold rating mean?

Analyst Recommendations for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.